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Abstract: Epilepsy is a common chronic disorder that requires long-term antiepileptic drug 
therapy. Approximately one half of patients fail the initial antiepileptic drug and about 35% 
are refractory to medical therapy, highlighting the continued need for more effective and 
better tolerated drugs. Levetiracetam is an antiepileptic drug marketed since 2000. Its novel 
mechanism of action is modulation of synaptic neurotransmitter release through binding to 
the synaptic vesicle protein SV2A in the brain. Its pharmacokinetic advantages include rapid 
and almost complete absorption, minimal insigniﬁ  cant binding to plasma protein, absence of 
enzyme induction, absence of interactions with other drugs, and partial metabolism outside 
the liver. The availability of an intravenous preparation is yet another advantage. It has been 
demonstrated effective as adjunctive therapy for refractory partial-onset seizures, primary 
generalized tonic-clonic seizures, and myoclonic seizures of juvenile myoclonic epilepsy. In 
addition, it was found equivalent to controlled release carbamazepine as ﬁ  rst-line therapy for 
partial-onset seizures, both in efﬁ  cacy and tolerability. Its main adverse effects in randomized 
adjunctive trials in adults have been somnolence, asthenia, infection, and dizziness. In children, 
the behavioral adverse effects of hostility and nervousness were also noted. Levetiracetam is 
an important addition to the treatment of epilepsy.
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Introduction – long-term management 
considerations in epilepsy
Epilepsy is a chronic condition characterized by recurrent unprovoked epileptic seizures. 
Epileptic seizures are the clinical manifestations including symptoms and signs of an 
abnormal, excessive, and hypersynchronous electrical discharge of neurons in the 
brain. Thus, a seizure is a symptom. Epilepsy is a condition; it cannot be considered a 
disease because it can be caused by many etiologies. Epilepsy may be genetic or could 
be the result of a variety of insults to the brain, including head trauma, stroke, vascular 
malformations, or congenital brain malformations (Engel 2001). Because seizures 
and epilepsy are very heterogeneous they have to be classiﬁ  ed. The most widely used 
classiﬁ  cation is that proposed by the International League Against Epilepsy in 1981, 
dividing seizures into those that are partial and those that are generalized (Commission 
1981). Partial seizures are ones in which the ﬁ  rst clinical and electrographic changes 
suggest initial activation limited to part of one cerebral hemisphere. Partial seizures 
are further subdivided into simple partial, complex partial and partial becoming 
generalized. Simple partial seizures are those in which awareness and responsiveness 
are completely preserved. Complex partial seizures involve at least an alteration of 
responsiveness or awareness. Secondarily generalized seizures can start either as simple 
partial or complex partial, but then spread to the whole brain and most often manifest 
towards their later part with generalized tonic and then clonic activity. Generalized 
seizures are those in which the ﬁ  rst clinical changes indicate initial involvement of 
both hemispheres. Consciousness is usually impaired at onset, except for myoclonic Neuropsychiatric Disease and Treatment 2008:4(3) 508
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seizures which are too brief for altered consciousness to be 
appreciated. Motor manifestations are bilateral if they occur. 
The initial electrographic ictal patterns are bilateral. General-
ized seizure types include generalized absence, generalized 
myoclonic, generalized tonic, generalized clonic, generalized 
tonic clonic, and generalized atonic seizures.
In addition to the classiﬁ  cation of epileptic seizures, the 
International League Against Epilepsy proposed a classiﬁ  -
cation of epilepsies and epileptic syndromes (Commission 
1981, 1989). Since most patients have either partial seizure 
types or generalized seizure types, the two main subdivisions 
in the classiﬁ  cation are partial (focal, local, or localization-
related) epilepsies, and generalized epilepsies. Each of these 
major categories is sub-classiﬁ  ed into those epilepsies that 
are idiopathic and presumed genetic or symptomatic/cryp-
togenic (probably symptomatic), related to a brain insult. In 
general, idiopathic epilepsies respond better to treatment than 
symptomatic epilepsies. Within this epilepsy classiﬁ  cation 
are epileptic syndromes that are characterized by a speciﬁ  c 
range of age at onset, speciﬁ  c seizure types, speciﬁ  c natural 
history or course, and speciﬁ  c response to treatment. For 
example, juvenile myoclonic epilepsy is a type of idiopathic 
generalized epilepsy in which patients have generalized 
myoclonic seizures, particularly after awakening, general-
ized tonic clonic seizures (in about 90%), and generalized 
absence seizures (in about 30% of cases). In this syndrome, 
the electroencephalogram (EEG) shows generalized 
4–6 Hz spike-and-wave discharges in between seizures. 
These patients respond well to treatment but their epilepsy is 
a lifelong condition (Renganathan and Delanty 2003). Some 
forms of epilepsy are known to have a limited course, with 
remission expected. For example, benign childhood epilepsy 
with centrotemporal spikes, also called benign rolandic epi-
lepsy, is an epileptic syndrome in which seizures are usually 
infrequent, easily controlled, and remit at puberty (Wirrell 
1998). However, most epilepsies are chronic and require 
long-term therapy.
The treatment of epilepsy will depend on appropriate 
classiﬁ  cation of the seizure type and the epileptic syndrome, 
then the choice of an antiepileptic drug (AED) that is most 
appropriate for the seizure type and epileptic syndrome 
and also the safest and most appropriate for the patient’s 
particular medical background. The treatment of epilepsy 
should always begin with monotherapy, using a low initial 
dose and titrating slowly. Among the more than sixteen 
marketed antiepileptic drugs approximately one half are 
older agents marketed before 1980, while the rest were 
marketed after 1990 (Table 1) (Schachter 2007). The older 
AEDs were generally approved for marketing and even 
used as ﬁ  rst-line agents without undergoing the rigorous 
clinical trials now required of the newer antiepileptic drugs. 
Regulatory approval for the new AEDs is restricted to the 
speciﬁ  c epilepsy patient populations in whom the drug has 
demonstrated efﬁ  cacy and to the speciﬁ  c mode of use in the 
relevant clinical trial. For example, a new AED will receive 
approval for ﬁ  rst-line monotherapy use only if demonstrated 
effective as ﬁ  rst-line monotherapy in a sound clinical trial. 
If the new AED is not started as ﬁ  rst-line monotherapy, 
but monotherapy is achieved after removal of an existing 
AED, then the regulatory approval will be for conversion to 
monotherapy only. Among the newer AEDs, the vast major-
ity were initially tested and approved for use as adjunctive 
therapy. Monotherapy trials typically followed later. Such 
trials have earned several AEDs approval for monotherapy 
use. However, the regulatory agencies are not uniform in 
their criteria for approval of AED indications: some agents 
have been approved for monotherapy in Europe but not in 
the US.
If seizures continue despite maximum tolerated doses 
of the ﬁ  rst AED, a change in therapy is indicated. Although 
an alternative monotherapy is usually recommended at this 
point, there is no scientiﬁ  c evidence to support the strategy 
of alternative monotherapy over adjunctive therapy (Kwan 
and Brodie 2000b; Beghi et al 2003). In general, common 
sense would decree that if the ﬁ  rst drug is not tolerated or 
if it is totally ineffective, alternative monotherapy is the 
best approach. If the ﬁ  rst drug was well tolerated and was 
at least partially effective, adjunctive therapy could be 
considered. The choice of ﬁ  rst alternative monotherapy or 
add-on therapy depends on several factors, including safety, 
tolerability, efﬁ  cacy in clinical trials, ease of use, potential 
for rapid titration, pharmacokinetic interactions, efﬁ  cacy in 
co-morbidities, and less prominently mechanism of action. If 
adjunctive therapy is chosen, potential interactions between 
the ﬁ  rst and the second AED are important factors in the 
choice of AED (Patsalos and Perucca 2003). Patients who 
fail a second AED are much less likely to become seizure 
free with the third next AED than those who have failed 
only one AED (Kwan and Brodie 2000a). After failure of 
two or three AEDs, patients with partial epilepsy should be 
considered for epilepsy surgery, which is highly effective 
in certain “surgically remediable” epileptic syndromes such 
as temporal lobe epilepsy with hippocampal sclerosis or 
focal epilepsy associated with certain benign brain lesions. 
Patients who are not excellent candidates for epilepsy 
surgery can undergo additional AED trials, including AED Neuropsychiatric Disease and Treatment 2008:4(3) 509
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combinations. In general it is advisable to avoid combinations 
of more than three AEDs because of the risk of interactions 
and additive adverse effects. Non-pharmacological therapies 
such as vagus nerve stimulation and the ketogenic diet or 
modiﬁ  ed Atkins diet can also be considered in patients who 
fail to respond to or are unable to tolerate antiepileptic drugs. 
However, vagus nerve stimulation is unlikely to produce 
seizure freedom, and compliance with the ketogenic or Atkins 
diet can be a major challenge.
Even though the landmark study of Kwan and Brodie 
suggested that the chances of seizure freedom with a new 
AED decrease with the failure of each additional AED, one 
survey of patients who failed epilepsy surgery evaluation 
found that 21% had achieved seizure remission at follow 
up, most often due to the addition of one of the new AEDs 
(Selwa et al 2003). Levetiracetam, the focus of this review 
is one of these new AEDs.
Levetiracetam
Levetiracetam (LEV) is one of the newest AEDs, marketed 
worldwide only since 2000. It was initially approved in the 
US only as adjunctive therapy for partial-onset seizures. 
However, more recent trials earned it approval as adjunctive 
therapy for primary generalized tonic-clonic seizures and 
myoclonic seizures of juvenile myoclonic epilepsy, and a 
recent comparative monotherapy trial earned it approval for 
use as initial monotherapy in the European Union, though 
not in the US. In addition, the recent approval and marketing 
of an intravenous preparation has added to the versatility 
of this AED.
Levetiracetam pharmacology
LEV is rapidly and almost completely absorbed after oral 
intake, with peak plasma concentrations approximately one 
hour after oral administration. Food reduces the peak plasma 
concentration by 20% and delays it by 1.5 hours, but does not 
reduce LEV bioavailability (Patsalos 2000, 2003). There is a 
linear relationship between LEV dose and LEV serum level 
over a dose range of 500–5000 mg (Radtke 2001). LEV pro-
tein binding, at less than 10%, is not clinically relevant. LEV 
metabolism is not dependent on the liver cytochrome P450 
enzyme system. LEV is predominantly excreted unchanged 
through the kidneys, with only about 27% metabolized. 
The main metabolic pathway is hydrolysis of the acetamide 
group in the blood (Radtke 2001). The resultant metabolite 
generated is inactive. LEV plasma half-life is 7 ± 1 hours 
in adults, but can be prolonged by an average of 2.5 hours 
in the elderly, most likely due to decreased creatinine clear-
ance with age (French 2001; Hirsch et al 2007). In patients 
with impaired renal function, a dose adjustment is needed, 
dependent on the creatinine clearance (French 2001). The 
absence of hepatic metabolism and of protein binding predict 
absence of pharmacokinetic interactions (Nicolas et al 1999). 
Indeed, no pharmacokinetic interactions were observed 
with phenytoin, warfarin, digoxin, or oral contraceptives 
(Browne et al 2000; Levy et al 2001; Patsalos 2000, 2003; 
Table 1 Spectrum of efﬁ  cacy of standard (A), and new AEDs (B). The new AEDs are listed in the order of their marketing in the US, 
following approval by the US Food and Drug Administration
    Partial  1ary GTC  G myoclonic  G absence
A Phenytoin  +  +  -  -
 Carbamazepine  +  +  -  -
 Valproate  +  +  +  +
 Phenobarbital +  +  -  -
 Primidone  +  +  +  -
 Ethosuximide -  -  -  +
 Methsuximide + ?  ?  +
 Clonazepam  +  +  +  +
B Felbamate  +b  + ?  ?
 Gabapentina  +b  -  -  -
 Lamotriginea  +b  +b ?  +b
 Topiramatea  +b  +b ?  ?
 Tiagabine  +b ?  -  -
 Oxcarbazepinea  +b  +?  -  -
 Levetiracetama  +*  +b  +b ?
 Zonisamide  +b  +  + ?
 Pregabalin  +b ?  -  -
aNew AED with positive initial monotherapy trials.
bNew AED efﬁ  cacy indication supported by blinded trials.Neuropsychiatric Disease and Treatment 2008:4(3) 510
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Ragueneau-Majlessi et al 2001, 2002; Abou-Khalil et al 
2003; Coupez et al 2003). However, some studies have sug-
gested lower LEV levels or higher LEV clearance in patients 
taking enzyme-inducing AEDs (May et al 2003; Perucca 
et al 2003; Hirsch et al 2007). Autoinduction probably does 
not occur with LEV, but one study involving short intensive 
monitoring suggested a drop in serum levels after the ﬁ  fth 
day of administration (Stefan et al 2006).
Intravenous levetiracetam
The intravenous formulation of LEV was demonstrated 
bioequivalent to the oral formulation (Ramael et al 2006b). 
In the initial study 1,500 mg of LEV were injected over 
15 minutes (Ramael et al 2006b). The infusion was well toler-
ated and adverse effects were similar to those with oral LEV, 
though somnolence was more common with the intravenous 
administration. In a second study, higher doses and faster 
infusion rates were used (2,000, 3,000, and 4,000 mg over 
15 min; 1,500, 2,000, and 2,500 mg over 5 min) (Ramael et al 
2006a). The most common adverse experiences, dizziness 
and somnolence, were not clearly related to dose or infusion 
rate. As expected, the peak plasma level was reached at 
5 or 15 minutes, corresponding to the end of the infusion, but 
otherwise the pharmacokinetic proﬁ  le was similar to that of 
oral LEV. LEV infusion over 15 minutes was demonstrated 
to be a practical alternative in epilepsy patients unable to 
take the oral medication (Baulac et al 2007).
Pharmacology in children, infants, and neonates
Pharmacokinetics in children were studied in 15 boys and 
nine girls 6–12 years old who received a single dose of LEV, 
20 mg/kg as an adjunct to their stable regimen of a single 
concomitant AED (Pellock et al 2001). The half-life was 
6 ± 1.1 hours. The C-max and area under the curve were lower 
in children than in adults and renal clearance was higher. 
The apparent body clearance was 1.43 ± 0.36 mL/min/kg, 
30%–40% higher in children than in adults. In another study 
in younger children and infants, the same dose/Kg was 
administered as a 10% oral solution to thirteen subjects aged 
2.3–46.2 months. The mean half-life was 5.3 ± 1.3 hours 
in this younger group (Glauser et al 2007). The half-life is 
likely longer in neonates. Two studies estimated LEV half-
life in the neonate at 18 hours (Allegaert et al 2006; Tomson 
et al 2007).
Pharmacokinetics during pregnancy
Maternal plasma concentrations measured during the third 
trimester were compared to a “baseline” before pregnancy 
or after delivery in two small studies (Tomson et al 2007; 
Westin et al 2008). Both studies found plasma concentrations 
to be signiﬁ  cantly lower during the third trimester in com-
parison with baseline. The mean concentration-to-dose ratio 
in the third trimester was 50%–30% of that at baseline. This 
suggested that the elimination of LEV may be enhanced dur-
ing pregnancy. However, there was great variability between 
patients, such that the change in serum concentration could 
not be accurately predicted.
Serum levels
LEV has linear kinetics, such that in any individual the 
serum concentration is proportional to the dose (Patsalos 
2004). However, the effective serum level for LEV is not 
known. One study in 69 patients taking 500–3000 mg/day 
found that the trough plasma concentration ranged from 1.1 
to 33.5 µg/mL (Lancelin et al 2007). Similar mean concen-
trations were found in patients experiencing adverse effects 
and those without adverse effects (11.2 vs 10.9 µg/mL). 
The mean plasma concentrations in responders and non-
responders were 12.9 and 9.5 µg/mL. The difference was not 
signiﬁ  cant, but the authors suggested that 11 µg/mL could 
be a threshold concentration for a therapeutic response. The 
vast majority of patients in this study had refractory epilepsy, 
making it difﬁ  cult to study the effective plasma concentration 
of LEV. Such a study is best conducted in patients with new 
onset epilepsy. A trial comparing LEV and carbamazepine 
in newly diagnosed patients did not report plasma concentra-
tions (Brodie et al 2007). However, it found that most patients 
were seizure-free at the lowest LEV dose of 1000 mg/day. In 
the therapeutic drug monitoring study mentioned earlier, a 
daily dose of 1000 mg/day was associated with a mean trough 
level of 6.5 ± 2.4 µg/mL (Lancelin et al 2007). Even though 
a therapeutic and toxic LEV concentration are not deﬁ  ned, 
measuring the serum concentration is helpful to assess 
compliance. In addition, if a baseline serum concentration is 
obtained during a period of good seizure control, the serum 
concentration can be repeated with breakthrough seizures to 
assess if a drop in concentration played a role. Finally, moni-
toring serum concentration through the course of pregnancy 
can help with calculating the recommended dose adjustments 
needed to correct for increased clearance.
Putative mechanism of action
LEV is different in its mechanism from that of other AEDs, 
because it is not effective in the standard animal models used 
to screen for anticonvulsant activity, while it is effective 
in the chronic kindling model (Loscher and Honack 1993; 
Klitgaard et al 1998). It was recently established that the Neuropsychiatric Disease and Treatment 2008:4(3) 511
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most relevant LEV mechanism of action is through binding 
to the synaptic vesicle protein SV2A (Lynch et al 2004). The 
SV2A binding afﬁ  nity of LEV derivatives correlated strongly 
with their binding afﬁ  nity in the brain, as well as with their 
ability to protect against seizures in the audiogenic mouse 
model (Lynch et al 2004). Similar ﬁ  ndings were noted in the 
mouse corneal kindling model and the GAERS rat model 
of generalized absence epilepsy (Kaminski et al 2008). The 
speciﬁ  c effect of LEV binding to SV2A appears to be a reduc-
tion in the rate of vesicle release (Yang et al 2007). LEV has 
other mechanisms of action that likely play a comparatively 
smaller role: reversing the inhibition of neuronal GABA- and 
glycine-gated currents by the negative allosteric modulators 
zinc and ß-carbolines (Rigo et al 2002), and partial depression 
of the N calcium current (Niespodziany et al 2001; Lukyanetz 
et al 2002). At present, the mechanisms of action have not yet 
helped identify a speciﬁ  c clinical efﬁ  cacy proﬁ  le for LEV.
Levetiracetam efﬁ  cacy – pivotal double-
blinded randomized controlled trials
Adjunctive therapy in refractory partial epilepsy 
in adults
LEV was found efﬁ  cacious in 3 pivotal placebo-controlled 
randomized blinded clinical trials in adults with refrac-
tory partial epilepsy. These trials investigated three doses, 
1000, 2000, and 3000 mg/day. All three doses were found 
to be effective. The US trial compared 1000 mg/day and 
3000 mg/day (in two divided doses) with placebo (Cereghino 
et al 2000). The study randomized 294 patients, 268 of whom 
completed the 14 weeks of treatment. After a 12-week single-
blind baseline, LEV was titrated over 4 weeks. Patients 
in the 1000 mg/day group ﬁ  rst received 333 mg/day for 
2 weeks, then 666 mg/day for 2 weeks, while patients in 
the 3000 mg/day group received 1000 mg/day for 2 weeks 
and then 2000 mg/day for 2 weeks. The median percentage
reduction in seizures over baseline was 32.5% for LEV 
1000 mg/day and 37.1% for LEV 3000 mg/day as compared 
with 6.8% for placebo. The 50% responder rates were 33% 
for 1000 mg/day and 39.8% for 3000 mg/day, compared 
with 10.8% for placebo. Seizure freedom was noted in 3% of 
patients in the 1000 mg group and 8% of the 3000 mg group. 
No patients were seizure-free in the placebo group. Maximum 
efﬁ  cacy was already present in the ﬁ  rst visit 2 weeks after 
initiating titration.
The European placebo-controlled randomized double-
blind trial compared 2000 mg/day, 1000 mg/day, and placebo 
as add-on treatment (Shorvon et al 2000). Patients random-
ized to 2000 mg/day received 500 mg bid for 2 weeks, then 
1000 mg bid while patients randomized to 1000 mg/day 
received placebo for 2 weeks, then 500 mg bid. The 4-week 
titration period was followed by a 12-week maintenance 
phase. Out of 324 randomized patients, 278 completed the 
study. There was a 26.5% median seizure reduction from 
baseline for the 2000 mg/day group, 17.7% for the 1000 
mg/day group, and 6.1% for the placebo group. The 50% 
responder rate was 31.6% for the 2000 mg/day group, 22.8% 
for the 1000 mg/day group, and 10.4% for the placebo 
group. Two percent of the 2000 mg patients, 5% of the 1000 
mg patients, and 1% of the 112 mg placebo patients were 
seizure free. In both the US and European trials, both doses 
tested were more efﬁ  cacious than the placebo, but were not 
signiﬁ  cantly different from each other.
A third pivotal trial, also conducted in Europe, only com-
pared 3000 mg per day to a placebo (Ben-Menachem and 
Falter 2000). After the baseline phase, patients randomized to 
LEV received 1000 mg/day for 2 weeks, then 2000 mg/day 
for 2 weeks before receiving 3000 mg/day for the remainder 
of the trial. The median reduction in seizure frequency from 
baseline was 39.9% for LEV compared with 7.2% for pla-
cebo. The responder rate was 50% for LEV compared with 
16.7% for placebo. Seizure freedom was reported in 8.2% of 
LEV patients compared with 1% of placebo patients.
The ﬁ  ndings from the above trials were conﬁ  rmed in 
a smaller blinded trial (94 patients) conducted in Taiwan, 
comparing adjunctive 2000 mg/day of LEV to placebo (Tsai 
et al 2006). The responder rate in the LEV group was 53.5% 
compared with 10.6% in the placebo group. Seizure freedom 
was observed in 8.7% of LEV patients, but none of the 
placebo patients.
The three main pivotal trials received a number of post 
hoc analyses. Two of these analyses addressed the latency 
for onset of action of LEV. In one study, it was found that the 
increase in proportion of seizure-free patients over baseline 
was 15% for the ﬁ  rst day of treatment and 17% for second 
and third days of treatment for 1000 mg/day, all statistically 
signiﬁ  cant (French and Arrigo 2005). However the increases 
for 333 mg/day were 7% for Day 1 and 9% for the second 
and third days. These were not signiﬁ  cant. There were no 
major changes in the placebo group. In a second analysis, 
the mean proportion of seizure-free days were as computed 
during each week after initiation of treatment (French et al 
2005). The mean proportion of seizure-free days was greater 
in the LEV than the placebo group and the difference was 
observed as early as the ﬁ  rst week after initiation of treat-
ment. Interestingly, it was also greatest at that point in time, 
after which it dropped but remained fairly stable. A similar Neuropsychiatric Disease and Treatment 2008:4(3) 512
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observation was made in the Taiwanese study, with initial 
69% reduction in seizure frequency at the 2-week visit after 
starting LEV, compared with only 37.5% reduction at the 
end of the study (Tsai et al 2006).
Another post hoc analysis addressed the number of 
seizure-free days (Leppik et al 2003a). Addition of LEV 
increased the number of days without seizures by 5.19 per 
quarter. An additional analysis addressed the affect of LEV 
on subtypes of partial seizures in the pooled data from the 
three major pivotal trials (Leppik et al 2003b). A statistically 
signiﬁ  cant reduction in the frequency of all partial seizures 
subtypes was observed. In addition, there was an independent 
reduction of secondarily generalized seizures over and above 
the reduction of partial seizures.
Add-on treatment for refractory partial 
seizures in children
One pediatric double-blind, placebo-controlled, randomized 
trial was performed in the US (Glauser et al 2006), in which 
216 patients were randomized, but 198 patients provided 
evaluable data. The target dose of LEV was 60 mg/kg/day 
in 2 divided doses. Patients ﬁ  rst received 20 mg/kg/day for 
2 weeks, then 40 mg/kg/day for 2 weeks before reaching the 
ﬁ  nal target dose. Patients unable to tolerate 60 mg/kg/day 
could be reduced to 40 mg/kg/day. The median percent-
age seizure reduction from baseline was 43.8% for LEV 
compared with 23.3% for placebo. For the whole treatment 
period, the median reduction was 43.3% for LEV compared 
with 16.3% for placebo. The 50% responder rate was 44.6% 
for LEV and 19.6% for placebo. The above results were all 
statistically signiﬁ  cant in favor of LEV. Seizure freedom 
was reported in 6.9% of LEV patients compared to 1% of 
placebo patients.
Monotherapy in new onset epilepsy
LEV was compared to controlled release carbamazepine in 
patients with newly diagnosed epilepsy in a double-blind 
trial (Brodie et al 2007). Patients enrolled in the study were 
adults with 2 or more partial or generalized tonic-clonic 
seizures in the previous year. The initial dose assigned was 
either LEV 500 mg twice a day or controlled-release carba-
mazepine (CBZ-CR) 200 mg twice a day. The dose could 
then be increased if a seizure occurred within 26 weeks of 
stabilization, with a maximum of 1,500 mg bid of LEV or 
600 mg bid of CBZ-CR. Patients who were seizure free for 
6 months continued on treatment for another 6 months. The 
intent to treat population included 285 patients randomly 
assigned to LEV and 291 patients assigned to CBZ-CR. 
The per protocol population (no major protocol deviations 
affecting efﬁ  cacy) included 237 and 235 patients at 6 months 
and 228 and 224 patients at 1 year for LEV and CBZ-CR. At 
6 months, 73% of LEV and 72.8% of CBZ-CR patients were 
seizure free, and at 1 year 56.6% of LEV and 58.5% of CBZ-
CR patients were seizure free, based on the per protocol 
population. Withdrawal rates for adverse events were 14.4% 
with LEV and 19.2% with CBZ-CR, based on the intent to 
treat population. The difference was not signiﬁ  cant.
Approximately 80% of patients experienced at least one 
adverse event in both groups. There was not much difference 
between the two groups with respect to the adverse events 
reported, except that more patients in the LEV group reported 
depression and insomnia while more patients in the CBZ-
CR group reported back pain. This study was unique among 
comparative newly diagnosed epilepsy trials in that it used a 
controlled-release preparation of carbamazepine. It also had 
a ﬂ  exibility in dosing that gave each agent the best chances 
of success with limited adverse experiences. The lowest dose 
levels produced seizure freedom at 6 months in the major-
ity of patients in both groups (59.1% of LEV patients and 
62.1% of CBZ-CR patients). Thus, 80.1% of LEV patients 
who were seizure free at 6 months did become seizure free 
at the starting dose (Brodie et al 2007).
This adequately powered study showed that LEV was 
not inferior to CBZ-CR in the treatment of newly diagnosed 
patients with epilepsy. Based on the results LEV was granted 
an indication for monotherapy in newly diagnosed patients 
in the European Union. However, this trial did not satisfy 
US Federal Drug Administration (FDA) requirements for 
monotherapy indications.
Adjunctive therapy in patients with idiopathic 
generalized epilepsy and generalized 
tonic-clonic seizures
LEV was compared with placebo as add-on therapy in a 
double-blind study in patients with idiopathic generalized 
epilepsy (Berkovic et al 2007). Patients were required to 
have at least 3 generalized tonic-clonic seizures during 
an 8-week (4-week retrospective and 4-week prospective) 
baseline. The study allowed enrollment of patients aged 
4–65 years. However, only about 10% of patients were 
under 16 years of age. Patients were receiving one or two 
baseline antiepileptic drugs. The dose of LEV used was 
3,000 mg/day or 60 mg/kg/day for children younger than 
16 years and weighing less than 50 kg. At the end of the base-
line period patients were started on LEV 1,000 mg/day for 
2 weeks, then 2,000 mg/day for 2 weeks, then 3,000 mg/day. Neuropsychiatric Disease and Treatment 2008:4(3) 513
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The corresponding doses for children were 20 mg/kg/day, 40 
mg/kg/day, then 60 mg/kg/day. Patients unable to tolerate 
the ﬁ  nal target dose were allowed to reduce their dose back 
to the previous value of 2,000 mg/day or 40 mg/kg/day. The 
primary efﬁ  cacy parameter was reduction in generalized 
tonic-clonic seizure frequency from baseline. A total of 164 
patients were randomized, 80 to LEV, and 84 to placebo. In 
each group 70 patients completed the evaluation. The primary 
efﬁ  cacy variable was signiﬁ  cant in favor of the LEV-treated 
group: the mean percentage reduction in weekly frequency 
was 56.5% for LEV and 28.2% for placebo (p = 0.004), and 
the median percentage reduction was 77.6% for LEV and 
44.6% for placebo (p   0.001). The 50% responder rate 
was 72.2% for LEV and 45.2% for placebo (p   0.001). As 
previously noted in the add-on trials for partial epilepsy, there 
was a rapid onset of action with 64.6% of patients classiﬁ  ed 
as responders at the lowest dose of 1,000 mg/day. There was 
no evidence of seizure exacerbation; fewer patients in the 
LEV than in the placebo group experienced a 25% or greater 
increase in GTC frequency. The percentage of GTC seizure-
free patients was 34.2% in the LEV and 10.7% in the placebo 
groups (p   0.001). A slightly smaller percentage of patients 
were free of all seizure types (24.1 vs 8.3%; p = 2.009). LEV 
was well tolerated in this trial, with only 1.3% of LEV and 
4.8% of placebo patients discontinuing treatment due to an 
adverse experience. The proportion of patients with at least 
one adverse experience was comparable in the two groups. 
Fatigue, somnolence, headache, and irritability were the only 
adverse experiences considered drug-related and reported in 
more than 5% of patients. This trial earned LEV approval 
for adjunctive therapy in the treatment of generalized tonic-
clonic seizures in idiopathic generalized epilepsy.
Adjunctive therapy in patients with refractory 
myoclonic seizures
LEV was recently studied in a double-blind multicenter 
randomized placebo-controlled study trial in adolescents and 
adults with idiopathic generalized epilepsy with myoclonic 
seizures (Noachtar et al 2008). Patients had to be 12 years or 
older and had to be experiencing at least 8 days with myo-
clonic seizures during the 8-week baseline period. The study 
design included a single-blind baseline period of 8 weeks, a 
4-week titration period, and a 12-week maintenance period. 
Patients were started on 1,000 mg/day of LEV for 2 weeks, 
then 2,000 mg/day for 2 weeks, then 3,000 mg/day for the 
maintenance period. Patients unable to tolerate this dose 
were allowed to reduce their dose to the previous level 
of 2,000 mg/day. The primary efﬁ  cacy endpoint was the 
responder rate with respect to the number of days with 
myoclonic seizures. Of the 122 patients randomized, the vast 
majority had a diagnosis of juvenile myoclonic epilepsy. 
Sixty patients receiving LEV and 60 receiving placebo could 
be analyzed. Among LEV patients, 58.3% had at least 50% 
reduction in myoclonic seizure days, compared with 23.3% 
of placebo patients (p   0.001). Very similar results were 
obtained when evaluating days with any seizure type. Free-
dom from myoclonic seizures was reported in 16.7% of LEV 
patients compared with only 3.3% of placebo patients during 
the whole treatment period and in 25% of LEV patients and 
5% of placebo patients during the 12-week evaluation period 
(p   0.005). When assessing freedom from all seizures, 
13.3% of LEV and 0% of placebo patients were seizure 
free during the whole treatment period and 21.7% of LEV 
and 1.7% of placebo patients were seizure free during the 
12-week evaluation period (p   0.001). This study earned 
LEV approval as adjunctive therapy in patients with myo-
clonic seizures. In fact, LEV is the only new antiepileptic 
drug with such approval.
The above study reported generalized tonic-clonic 
seizures in 41 LEV and 40 placebo patients, and absence 
seizures in 29 LEV and 21 placebo patients. However, the 
study was not designed to evaluate these seizure types. No 
worsening was reported for either seizure type.
Levetiracetam efﬁ  cacy in speciﬁ  c patient 
subsets or speciﬁ  c syndromes
LEV was studied in several non-blinded trials in spe-
ciﬁ  c patient populations. Some of these will be brieﬂ  y 
reviewed.
Subsets of partial epilepsy
No blinded randomized trial speciﬁ  cally evaluated subsets 
of partial epilepsy based on localization or on prior epilepsy 
surgery. However, one study reported that patients with 
temporal lobe epilepsy were more likely to be improved 
than patients with frontal lobe epilepsy (Bazil et al 2002). 
In another study, patients who had failed epilepsy surgery 
were much more likely to respond to LEV than patients 
who had never been operated: 76.1% were responders and 
47.6% became seizure free compared with 34.3% responder 
rate and 14.7% seizure free rate in patients who never had 
epilepsy surgery (Motamedi et al 2003). In a study evaluating 
long-term outcome in patients who initially failed epilepsy 
surgery, newly administered LEV was a signiﬁ  cant positive 
prognostic factor for eventual seizure remission (Janszky 
et al 2005).Neuropsychiatric Disease and Treatment 2008:4(3) 514
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LEV efﬁ  cacy in community patients
A large open-label trial in 1,030 community patients in 
the US (KEEPER trial) demonstrated that adjunctive LEV 
therapy was more effective than noted in double-blind trials 
in highly refractory patients; 57.9% of patients were respond-
ers and 20% were seizure free (Morrell et al 2003). Another 
community-based trial conducted internationally (SKATE 
trial) also demonstrated higher responder and seizure-free 
rates than in the double-blind trials (Steinhoff et al 2005; 
Genton et al 2006; Lambrechts et al 2006).
Efﬁ  cacy in the elderly
A subset of patients from the KEEPER trial aged 65 and 
older were analyzed separately (Ferrendelli et al 2003). They 
had a better response than the group as a whole. 76.9% were 
responders and 40% were seizure free during the 16 weeks 
of the study. Another study found a better response to LEV 
in late-onset epilepsy (Bazil et al 2002).
Benign epilepsy of childhood with centrotemporal 
spikes (BECTS)
Children with BECTS do not always need to be treated 
because they may have a small number of seizures and 
the eventual outcome is favorable. However, treatment is 
often initiated in children with young age at onset, frequent 
seizures, and daytime secondarily generalized seizures. The 
ability to use an antiepileptic drug with favorable tolerability 
would make the decision to treat easier and less controversial. 
LEV was compared with oxcarbazepine (OXC) as mono-
therapy in children with newly diagnosed BECTS (Coppola 
et al 2007). The patients were aged 3–12 years, had a clear 
diagnosis of BECTS, a normal MRI, no neurological deﬁ  cits, 
and a reason for treatment such as frequent seizures. Children 
were randomized for treatment with either LEV or OXC. 
Both drugs were initiated at 5 mg/kg/day followed by a 3-day 
titration at increments of 5 mg/kg up to a maximum daily dose 
of 20 mg/kg. The titration stopped earlier if the medication 
was not tolerated. In case of seizure recurrence, the LEV dose 
could be increased up to 30 mg/kg and the OXC dose up to 
35 mg/kg. Twenty-one children were randomized to LEV 
and 18 to OXC. After follow-up for 12–24 months (mean 
18.5 months), 90.5% of LEV and 72.2% of OXC patients had 
no seizure recurrence. Adverse effects of LEV were reported 
in 3 children (14.3%) and OXC in 2 children (11.1%). The 
trial suggested that both LEV and OXC could be used in 
patients with BECTS. Favorable efﬁ  cacy and tolerability of 
LEV in BECTS was also suggested in extended case reports 
(Bello-Espinosa and Roberts 2003; Verrotti et al 2007).
Severe myoclonic epilepsy of infancy (SMEI)
SMEI is a rare epileptic syndrome usually related to a sodium 
channel mutation. The syndrome is characterized by highly 
refractory seizures (including generalized myoclonic, gener-
alized tonic-clonic, generalized absence, and partial seizures), 
and slowing or arrest of psychomotor development. There 
is a strong need for effective therapy in this syndrome. One 
adjunctive open-label multi-center trial conducted in Italy 
enrolled patients who had failed at least 2 AEDs and had at 
least 4 generalized tonic-clonic seizures during an 8-week 
historical baseline (Striano et al 2007). LEV was titrated up 
to 50–60 mg/kg/day. Twenty-three of 28 enrolled patients 
(82.1%) completed the 18-week trial. There was a signiﬁ  cant 
reduction in the weekly frequency of generalized tonic-clonic, 
myoclonic, and partial seizures, but not absence seizures. The 
responder rate was 64.2% for tonic-clonic seizures, 60% 
for myoclonic seizures, 60% for focal seizures, and 44% 
for absence seizures. Seizure freedom for speciﬁ  c seizure 
types was recorded in 2–3 patients for each of generalized 
tonic-clonic, generalized myoclonic, and focal seizures, but 
it was not clear how many patients were free of all seizures. 
An excellent response of SMEI to LEV was also reported in 
another study, with 3 out of 4 patients classiﬁ  ed as responders 
(Labate et al 2006). Thus LEV appeared particularly useful 
for this difﬁ  cult type of epilepsy.
Progressive myoclonic epilepsies
Progressive myoclonic epilepsy includes several speciﬁ  c con-
ditions in which myoclonus, both epileptic and nonepileptic, 
is a prominent manifestation. Seizures and myoclonus tend to 
be refractory, and new effective therapies are needed. LEV 
efﬁ  cacy was demonstrated in various progressive myoclonic 
epilepsy syndromes, mainly for the myoclonus. In one study 
of 13 patients with Unverricht Lundborg disease, 8 had a 
measurable improvement in myoclonus score, with the best 
effect in younger patients (Magaudda et al 2004). Marked 
improvement in myoclonus and quality of life was also 
reported in smaller groups (Kinrions et al 2003; Papacostas 
et al 2007). One other study reported beneﬁ  t in 3 of 6 patients 
with Unverricht-Lundborg disease and 2 of 3 with myo-
clonic epilepsy with ragged red ﬁ  bers (MERRF). However, 
there was long-term attenuation of initial efﬁ  cacy in 3 of 
the patients (Crest et al 2004). There was also 1 single case 
report of dramatic improvement in 1 patient with MERRF 
(Mancuso et al 2006), and a report of LEV beneﬁ  t in 2 sisters 
with Lafora body disease (Boccella et al 2003). Of note is 
that there have been several reports of LEV in non-epileptic 
myoclonus, with variable success (Frucht et al 2001; Genton Neuropsychiatric Disease and Treatment 2008:4(3) 515
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and Gelisse 2001; Krauss et al 2001; Keswani et al 2002; 
Schauer et al 2002; Imperiale et al 2003; Lim and Ahmed 
2005; Striano et al 2005).
Lennox-Gastaut and West syndrome
In patients with Lennox-Gastaut syndrome, a good response 
of myoclonic and tonic-clonic seizures was reported (De Los 
Reyes et al 2004). There was also some response of atonic sei-
zures, but tonic seizures were not responsive to treatment (De 
Los Reyes et al 2004). There are rare reports of LEV efﬁ  cacy 
in West syndrome (Lagae et al 2003; Lawlor and Devlin 2005). 
One study included a variety of epileptic syndromes, including 
West syndrome and Lennox-Gastaut syndrome (Lagae et al 
2003). Approximately 50% of patients were responders, with 
no signiﬁ  cant differences in efﬁ  cacy between generalized and 
partial epilepsy syndromes. The best results were observed for 
myoclonic seizures with 64% responders (Lagae et al 2003).
Other epileptic syndromes with myoclonic seizures
Several case series and open label trials investigated LEV 
use in epileptic syndromes that included myoclonic seizures. 
LEV efﬁ  cacy was most strongly demonstrated in juvenile 
myoclonic epilepsy, both as add-on therapy and monotherapy 
(Krauss et al 2003; Kumar and Smith 2004; Di Bonaventura 
et al 2005; Labate et al 2006; Specchio et al 2006; Sharpe et al 
2008). Particular beneﬁ  t was noted in previously drug-naïve 
patients. These reports complement the pivotal trials in juvenile 
myoclonic epilepsy, and also suggest that LEV could be con-
sidered for investigation as ﬁ  rst-line therapy in this condition. 
Anecdotal beneﬁ  t was reported in myoclonic astatic epilepsy, 
myoclonic absences, and benign myoclonic epilepsy in infancy 
(Labate et al 2006), and a dramatic improvement was reported 
in one patient with negative myoclonus (Gelisse et al 2003).
Epilepsy with continuous spikes and waves during 
slow wave sleep and Landau-Kleffner syndrome
One report of LEV use in 12 patients with continuous spikes 
and waves during slow sleep indicated that 7 patients (58.3%) 
showed improvement of the EEG, with 3 of them showing 
improvement on neuropsychological evaluation. Two other 
patients without improvement of the EEG had neuropsy-
chological improvement (Aeby et al 2005). Beneﬁ  t was also 
reported in another small series (Capovilla et al 2004). There 
was 1 case report of improvement in a child with the related 
Laudau-Kleffner syndrome (Kossoff et al 2003).
Photosensitive epilepsy
LEV abolished or suppressed the photoparoxysmal response 
on EEG in 9 of 12 patients with generalized photosensitive 
epilepsy, in a short-term trial designed to explore LEV effect 
in photosensitivity (Kasteleijn-Nolst Trenite et al 1996). There 
were no speciﬁ  c therapeutic trials in photosensitive epilepsy, 
but 1 paper reported excellent beneﬁ  t from LEV in one patient 
with refractory photosensitive epilepsy (Lagae et al 2003).
Generalized absence seizures
There have been no speciﬁ  c studies of LEV for generalized 
absence seizures. In the pivotal study of LEV in patients 
with myoclonic seizures, there was no signiﬁ  cant difference 
between LEV and placebo in reduction of seizure days with 
absence seizures (Andermann et al 2005). In another study of 
idiopathic generalized epilepsy, absence seizures were the 
least likely to respond to LEV (Krauss et al 2003). However, 
it should be noted that refractory absence is not necessarily 
representative of generalized absence seizures in general.
Status epilepticus and acute repetitive seizures
The rapid almost complete absorption of LEV and its rapid 
onset of action made it a candidate for use in acute seizure 
conditions. A number of case reports and case series have 
supported a role for oral LEV in the treatment of acute repeti-
tive seizures and status epilepticus that were refractory to 
initial therapy (Rossetti and Bromﬁ  eld 2005; Zaatreh 2005; 
Patel et al 2006; Rossetti and Bromﬁ  eld 2006; Rupprecht et al 
2007; Trabacca et al 2007; Alehan et al 2008). The largest 
study included included 23 patients with status epilepticus, 
10 of whom responded (Rossetti and Bromﬁ  eld 2006). The 
study found that response was more likely when LEV is 
administered early, and that additional beneﬁ  t was unlikely 
when the dose is escalated beyond 3000 mg/day. Since the 
advent of intravenous LEV, there have been several reports 
of successful use of intravenous LEV in the treatment of 
status epilepticus or acute repetitive seizures that had failed 
benzodiazepines or phenytoin ( Falip et al 2006; Farooq et al 
2007; Knake et al 2007; Schulze-Bonhage et al 2007; Abend 
et al 2008; Goraya et al 2008; Ruegg et al 2008). The larg-
est report described the result of treatment of 18 episodes of 
focal status epilepticus in 16 patients (Knake et al 2007). All 
had failed benzodiazepine therapy. The loading LEV dose 
varied from 250 to1500 mg, followed by daily maintenance of 
1500–7000 mg. Status epilepticus resolved after intravenous 
LEV in 16 episodes, and only 2 episodes required additional 
therapy (Knake et al 2007). No severe adverse experiences 
were reported in these studies, and LEV was usually well-
tolerated. These encouraging reports support the need for 
studies comparing LEV with other established therapies for 
various types of status epilepticus.Neuropsychiatric Disease and Treatment 2008:4(3) 516
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Prediction of LEV efﬁ  cacy
One study in 344 patients attempted to identify factors 
that predicted response to therapy (Kinirons et al 2006). 
In this study, 16.3% of patients were seizure free and 
42% were responders. Idiopathic generalized epilepsy and 
post-traumatic partial epilepsy were more common in the 
responder group (p = 0.005 and p = 0.05). In responders 
lamotrigine was used signiﬁ  cantly more often in combination 
with LEV (p = 0.003). Not unexpectedly, the mean daily LEV 
dose was lower in responders than non-responders.
Paradoxical increase in seizures
A paradoxical increase in seizures was noted at times, usually 
at elevated doses. In one study that focused on the paradoxical 
increase in seizures 40% of adults and 20% of children were 
responders, but 18% of adults and 43% of children had a 
greater than 25% increase in seizure frequency (Nakken et al 
2003). The increase in seizure frequency was more likely in 
mentally retarded patients and at relatively high doses. One 
other study showed that worsening of seizures was generally 
seen early in the titration phase (Coppola et al 2004).
Long-term maintenance of efﬁ  cacy
The report of development of tolerance in one animal model 
of epilepsy (Loscher and Honack 2000) prompted evalua-
tion of LEV long-term efﬁ  cacy in patients with epilepsy. Some 
of the long-term studies analyzed the trial data and others 
analyzed post marketing data. In the analysis of the trial data 
base, the continuation rate was 60% after 1 year (Krakow 
et al 2001). Factors that predicted continuation of LEV were 
a high maximal dose, a low starting dose, the presence of 
generalized tonic-clonic seizures, and a smaller number of 
AEDs at baseline. Thirteen per cent of the patients became 
seizure free for at least 6 months and 8% for at least 1 year; 
4.5% of patients became seizure free from the ﬁ  rst day of 
exposure until the cut-off point. The total trial population 
was divided into cohorts based on the duration of exposure 
(6-month increments) and the median percentage reduction 
in seizure frequency was examined for each of the cohorts 
(Ben-Menachem et al 2003). Overall, the median percentage 
reduction was 39.6% and there was no decline in that param-
eter within each cohort. In fact, the median percent reduction 
appeared to increase rather than decrease over time. During 
the last 6 months of treatment 11.7% of patients were seizure 
free overall. The stability of response was also evaluated by 
examining the percentage of responders in the ﬁ  rst 3 months 
who remained responders in the subsequent 3 months and 
the percentage of the latter who remained responders for the 
next 3 months (Abou-Khalil and Lazenby 2003). The analysis 
indicated that 73.6% of the 3-month responders remained 
responders for the next three months and 82% of these were 
still responders in the subsequent 3 months. Thus, LEV 
response appears to be maintained for the majority of patients, 
but a small percentage of individuals may have a reduction 
in beneﬁ  t while others may have an improvement.
The post-marketing studies had a similar conclu-
sion (Abou-Khalil and Lazenby 2003; Betts et al 2003; 
Ben-Menachem and Gilland 2003; Nicolson et al 2004; 
Depondt et al 2006; Kuba et al 2006). The retention rates 
at 1 year varied from 61% to 77% and seizure freedom rate 
varied from 16% to 26%. In one study, there was a slight 
reduction in seizure freedom from 32% at 6 months to 26% 
at 1 year (Betts et al 2003); among patients who were seizure 
free at 6 months, 74% were still seizure free at 1 year and 18% 
were still more than 90% improved, though no longer seizure 
free. Another study with follow-up for 1 to 2 years, 81.5% 
of patients who were seizure free in the ﬁ  rst 3 months were 
still seizure free in the last 3 months of treatment, but 39% 
of those who were seizure free in the last 3 months were not 
seizure free in the ﬁ  rst 3 months (Abou-Khalil and Lazenby 
2003). The phenomenon of AED tolerance may possibly be 
playing a role in a small proportion of patients treated with 
LEV. This phenomenon is recognized with other antiepi-
leptic drugs as well, but its degree is not clearly understood 
(Loscher and Schmidt 2006).
Levetiracetam tolerability
The initial placebo-controlled adjunctive trials in partial epi-
lepsy suggested that treatment emergent adverse events that 
had a higher frequency with LEV were somnolence, asthenia, 
dizziness, and infection (upper respiratory infections). Somno-
lence was the most common reason for LEV discontinuation 
in the US pivotal partial seizure trial (Cereghino et al 2000). 
Its frequency ranged from 5% to 20% in the adult pivotal 
trials (Ben-Menachem and Falter 2000; Cereghino et al 
2000; Shorvon et al 2000; Berkovic et al 2007; Brodie 
et al 2007; Noachtar et al 2008; ), and 23% in the pediatric trial 
(Glauser et al 2006). The most common adverse events did 
not seem dose related in the studies that evaluated more than 
one LEV dose (Cereghino et al 2000; Shorvon et al 2000). 
However, in one study comparing 2,000 and 4,000 mg/day 
without titration, somnolence was highest in patients receiving 
4,000 mg/day, affecting 44.7% (Betts et al 2000). Adverse 
effects generally appeared within the ﬁ  rst month of treatment. 
In one trial somnolence was reported in 10% of patients during 
LEV up-titration, but not in the evaluation period (Noachtar Neuropsychiatric Disease and Treatment 2008:4(3) 517
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et al 2008). Drowsiness seems more common in older age. 
In one post-marketing study comparing 151 younger adults 
(age 16–31 years) and 157 older adults (age 55–88 years), 
drowsiness was reported by 12% of the younger and 24.7% 
of the older group. It resulted in dose reduction or discontinu-
ation in 6.9 and 3.1% of the younger group and 15.1% and 
5.2% of the older group.
Behavioral/psychiatric adverse effects were not 
prominent in the initial adjunctive therapy trials in partial 
epilepsy. However, these were more prominent in subse-
quent trials performed in less refractory patients (Abou-
Khalil et al 2003). In a systematic review of LEV safety 
in the clinical trial population, non-psychotic behavioral 
symptoms occurred in 13.5% of LEV-treated patients with 
epilepsy versus 6% of placebo-treated patients (French 
et al 2001). The difference between placebo and LEV 
groups was small or non-existent in cognitive and anxiety 
studies, suggesting that behavioral adverse effects may 
be speciﬁ  c for epilepsy. It is also possible that the greater 
occurrence in epilepsy patients could be contributed to 
by higher dose in the epilepsy group. The non-psychotic 
behavioral symptoms that occurred in more than 1% of 
epilepsy patients in placebo-controlled trials were depres-
sion (3.8%), nervousness (3.8%), hostility (2.3%), anxiety 
(1.8%), and emotional lability (1.7%) (Cramer et al 2003). 
The proportion of patients with these symptoms was 
somewhat higher in an open-label study that included less 
refractory patients (Abou-Khalil et al 2003). Among 219 
patients in that study nervousness was reported in 9.6%, 
depression in 7.3%, hostility in 4.1%, personality disorder 
in 3.7%, emotional lability in 2.7%, and anxiety in 2.3% 
of subjects (Abou-Khalil et al 2003). Behavioral adverse 
events were severe in 7 of 219 patients (3.2%).
Behavioral adverse events may be more likely in certain 
patient groups. Learning disabilities were a predispos-
ing factor in one study that reported a 23% frequency of 
behavioral adverse effects when learning disability was 
present compared to 10% if learning disability was absent 
(Brodtkorb et al 2004). One other study indicated a greater 
frequency of behavioral adverse effects in patients with pre-
vious psychiatric history, history of febrile convulsions, and 
a history of status epilepticus, and a lower frequency when 
lamotrigine was used concomitantly with LEV (Mula et al 
2003, 2004). Similar risk factors were noted for psychiatric 
adverse effects with topiramate, suggesting that a subgroup 
of patients is generally prone to develop these adverse effects 
during AED therapy, independent of AED mechanism of 
action (Mula et al 2007).
Behavioral adverse events are most often mild and are not 
usually a cause of LEV discontinuation. However, behavioral 
adverse effects had a greater representation in patients who 
discontinued LEV, and may be the most common reason for 
discontinuation (Abou-Khalil and Lazenby 2003). In one 
large case controlled study, more than half of the patients 
who discontinued LEV did so because of behavioral issues, 
the most important of which were depression, irritability, 
and aggression (White et al 2003). Patients who discontin-
ued LEV because of behavioral adverse events were more 
likely to have symptomatic generalized epilepsy, history of 
psychiatric diagnosis, and a faster LEV titration (White et al 
2003). Behavioral adverse experiences were reported with a 
higher frequency in pediatric studies. In the pivotal pediatric 
adjunctive placebo-controlled trial, 5 behavioral/psychiatric 
adverse effects were reported in  5% of patients: hostility 
(12% of LEV and 6% of placebo), nervousness (10% of 
LEV vs 2% of placebo), personality disorder (8% of LEV 
vs 7% of placebo), emotional lability (6% of LEV vs 4% of 
placebo), and agitation (6% of LEV, 1% of placebo). None 
of these adverse events were seen in  5% of patients in 
the adult adjunctive partial epilepsy trials. In the adjunc-
tive generalized epilepsy trial, irritability occurred in 6.3% 
and mood swings in 5.1% of LEV-treated patients versus 
2.4% and 1.2% of placebo-treated patients (Berkovic et al 
2007). However, in the myoclonic seizure trial nervousness 
was reported in 3.3% of LEV-treated and 6.7% of placebo 
patients. In the newly diagnosed epilepsy trial, the main 
behavioral adverse effect reported was depression in 6.3% 
of LEV patients and 2.1% of carbamazepine-treated patients 
(Brodie et al 2007).
Behavioral adverse effects were reported more often in 
pediatric than adult case series (Glauser et al 2002; Wheless 
and Ng 2002; De Los Reyes et al 2004). However, improve-
ments in behavior were also common. In one study, 12.8% of 
children demonstrated aggression and 10.3% hyperactivity, 
but 25.6% had an improvement in behavior and/or cognition 
(Wheless and Ng 2002).
Psychosis has been reported rarely with LEV therapy 
(Kossoff et al 2001; Motamedi et al 2003; Youroukos et al 
2003). The symptoms were always reversed with LEV dis-
continuation. Psychosis may occur rarely with many AEDs, 
and is unlikely to be speciﬁ  c for LEV.
It is of note that LEV is not associated with serious sys-
temic adverse effects. One common concern, allergic rash 
is uncommon with LEV. In one large post-marketing study, 
the risk of rash with LEV use was 0.6%, signiﬁ  cantly lower 
than the average of all AEDs (Arif et al 2007).Neuropsychiatric Disease and Treatment 2008:4(3) 518
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Safety in pregnancy and breast feeding
Limited data are available on safety in pregnancy. In the 
analysis of the UK Epilepsy and Pregnancy Registry, 3 of 
117 exposed pregnancies had a major congenital malforma-
tion, but all three were also exposed to other AEDs (Hunt 
et al 2006). There were also no minor malformations in the 
LEV monotherapy group which included 39 monotherapy 
exposures. Other smaller reports also did not identify any 
LEV-related malformations (Long 2003; ten Berg et al 2005). 
Four infants exposed to LEV monotherapy had a low birth 
rate, but the mean birth weight for infants exposed to LEV was 
within the normal range (Hunt et al 2006). Thus, preliminary 
data seemed favorable, but additional reports are needed for 
deﬁ  nitive assessment of LEV safety during pregnancy.
LEV is extensively transferred from mother into breast 
milk. However, breast fed infants had very low LEV serum 
concentrations, suggesting that breastfeeding should not 
be contraindicated (Johannessen et al 2005; Tomson et al 
2007).
Quality of life
Quality of life measurements were incorporated in the 
US pivotal LEV trial. The QOLIE-31 questionnaire was 
administered at the end of the baseline period before ran-
domization and again at the end of the treatment period. It 
showed improvement in 3 of the 7 items: overall quality of 
life, seizure worry, and cognitive functioning (Cereghino 
et al 2000). The results were analyzed in greater detail in a 
separate publication (Cramer et al 2000). Statistically signiﬁ  -
cant improvements were found in seizure worry and overall 
quality of life in the LEV treatment group. The placebo group 
scores decreased for the cognitive functioning subscale and 
the total score. QOLIE scores were inﬂ  uenced by seizure 
control. Patients who had a 50% or greater improvement in 
seizures had signiﬁ  cant improvements in all areas compared 
with non-responders. The exception was medication effect. 
Therefore, LEV seemed to have a positive impact on health-
related quality of life.
One hundred and one patients who completed QOLIE-31 
at the end of double-blind treatment also completed the ques-
tionnaire during a long-term follow-up visit, approximately 
4 years after starting LEV (Cramer and Van Hammee 2003). 
All scales and the total score improved between the baseline 
and long-term assessments. The short-term improvement 
noted at the end of the double-blind treatment period was 
maintained in the long term, and patients who were random-
ized to placebo reached the same level of improvement in the 
long-term as patients who initially received LEV.
One recent study used QOLIE-31 at baseline, at 16 weeks 
of double-blind add-on treatment, then again at 40 weeks 
of treatment (now open treatment). Fourteen patients were 
randomized to LEV and 14 to placebo. Subscale scores on the 
QOLIE-31, including scores on Cognitive Functioning and 
Social Function improved only for the LEV group at the end 
of short-term treatment. At the end of the long-term phase, 
these improvements were maintained (Zhou et al 2008).
Cognitive function
LEV cognitive effects were examined in comparison to 
carbamazepine (CBZ) in 28 healthy volunteers, using a 
randomized, double-blind, two-period crossover design 
(Meador et al 2007). The doses were adjusted to mid-range 
therapeutic level, with a mean of 7.5 µg/mL for CBZ and 
32.2 µg/mL for LEV. CBZ was worse than LEV on 15 of 34 
variables tested, and better at none. Compared with baseline, 
CBZ was worse for 26 of 34 variables, and LEV was worse 
for 4 (Meador et al 2007).
There is no evidence of decline in cognitive function with 
LEV treatment in patients with partial epilepsy. One study 
compared LEV with topiramate (TPM) using standardized 
a neuropsychological test battery. Testing was performed 
before treatment and after reaching steady state in 30 con-
secutive patients with focal epilepsy treated with LEV and 
21 treated with TPM. Whereas the TPM group worsened 
in cognitive speed, verbal ﬂ  uency, and short-term memory, 
there was no change in the LEV group (Gomer et al 2007). 
Another study found that performance time on the Wisconsin 
Card Sorting Test and Delayed Logic Memory signiﬁ  cantly 
improved for 14 patients randomized to LEV, but not for 14 
randomized to placebo (Zhou et al 2008).
Place of levetiracetam in therapy
Partial epilepsy
LEV has not been compared directly to other new AEDs, but 
meta-analysis of controlled partial epilepsy adjunctive trials 
suggested that LEV had a favorable ‘responder-withdrawal 
ratio’ in comparison with other agents (Marson et al 2001; 
Otoul et al 2005; Zaccara et al 2006). Based on the favor-
able efﬁ  cacy and tolerability of LEV as an add-on therapy in 
refractory partial epilepsy, it is reasonable to consider it one 
of the ﬁ  rst add-on therapies in these patients. Other factors 
that argue for this are the absence of drug – drug interactions 
and the rapid onset of action, which means that it will rapidly 
become clear whether LEV will be effective. However the 
choice of therapy is inﬂ  uenced by many factors including 
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favor adjunctive therapy with an AED that can cause weight 
loss, for example topiramate or zonisamide. Psychiatric co-
morbidity may also argue against choosing LEV as initial 
adjunctive therapy.
The place of LEV as an initial monotherapy is less clear 
cut. There is now a well designed monotherapy study that 
showed non-inferiority to controlled-release carbamazepine 
(Brodie et al 2007), likely to satisfy the criteria of the Thera-
peutics and Technology Assessment Subcommittee of the 
American Academy of Neurology and the American Epilepsy 
Society for initial monotherapy use (French et al 2004). LEV 
has approval by the European Medicines Agency but not the 
US FDA for initial monotherapy for partial onset seizures. 
Despite the absence of US FDA approval, there is ample 
evidence that LEV is widely used in the hospital setting for 
new onset epilepsy and acute seizures (Chabolla et al 2003; 
Glass et al 2005; Falip et al 2006; Di Bonaventura et al 2006; 
Szaﬂ  arski et al 2007). This was the case even before the 
appearance of the intravenous formulation, but the intrave-
nous formulation certainly has made this use more prevalent. 
The other antiepileptic drugs with intravenous formulations 
have associated disadvantages. Phenobarbital is highly sedat-
ing and both phenobarbital and phenytoin/fosphenytoin are 
enzyme inducing and could result in important unfavorable 
interactions. Intravenous valproate is safe and well toler-
ated, but potential adverse effects with long-term valproate 
use may be a deterrent to its use in hospitalized patients. 
As a result of the above, LEV has become frequently used 
in patients with seizures secondary to stroke, neurosurgical 
intervention, brain tumors, and other medical conditions 
(Chabolla et al 2003; Wagner et al 2003; Glass et al 2005; Di 
Bonaventura et al 2006; Falip et al 2006; Newton et al 2006, 
2007; Maschio et al 2006; Szaﬂ  arski et al 2007).
The IV formulation of LEV is currently approved for 
temporary replacement in patients who cannot take oral 
medication (Ramael et al 2006a, b; Baulac et al 2007). It is 
not approved for the treatment of status epilepticus. However, 
there are now several reports of the use of LEV (usually oral 
LEV) in refractory status epilepticus (Atefy and Tettenborn 
2005; Rossetti and Bromﬁ  eld 2005; Patel et al 2006; Rossetti 
and Bromﬁ  eld 2006; Rupprecht et al 2007; Schulze-Bonhage 
et al 2007), and it is certainly reasonable to consider IV LEV 
as one of the options for patients with non-convulsive partial 
status epilepticus as well as refractory status epilepticus, 
particularly in those patients who have recurrence of status 
in conjunction with anesthesia withdrawal. LEV may also 
play a role for patients who have to be started or restarted 
on LEV abruptly. The intravenous administration of LEV 
is associated with a peak level at the end of infusion in 5 or 
15 minutes, whereas the oral administration is associated 
with a peak at 1 hour, and the peak would be delayed if 
administration is with food (Ramael et al 2006a, b).
Generalized epilepsy
There is now deﬁ  nite evidence of LEV efﬁ  cacy as adjunctive 
therapy for patients with idiopathic generalized epilepsy and 
uncontrolled generalized tonic-clonic seizures or general-
ized myoclonic seizures (Berkovic et al 2007; Noachtar 
et al 2008). LEV can therefore be considered as an early 
adjunctive therapy in these conditions. In the case of myo-
clonic seizures, it is the only new antiepileptic drug with 
an FDA approved indication for this application (one older 
antiepileptic drug, clonazepam, also has FDA approval for 
myoclonic seizures).
LEV has no FDA indication and no pivotal trials sup-
porting initial monotherapy use in generalized epilepsy. 
However, the evidence of adjunctive efﬁ  cacy in juvenile 
myoclonic epilepsy has prompted use as initial monotherapy 
in juvenile myoclonic epilepsy. The anecdotal data has been 
very favorable (Specchio et al 2006; Sharpe et al 2008). 
However, the use of LEV as initial monotherapy cannot 
be strongly supported without a pivotal trial, for example a 
trial comparing it with valproate. In women of childbearing 
potential, valproate use is associated with unacceptable risks 
including teratogenicity in the event of pregnancy, weight 
gain, hair loss, and hormonal changes. As a result of these 
risks, it has become common in practice to use alternatives 
such as lamotrigine, topiramate, and zonisamide (Prasad et al 
2003). None of these drugs have pivotal trials supporting 
their use for juvenile myoclonic epilepsy. LEV could be 
added to that list, with the advantage of deﬁ  nitive evidence 
for efﬁ  cacy as add-on therapy. The one seizure type for 
which there is no data is absence seizures. Based on lack of 
data, LEV would not be an appropriate initial therapy for 
absence seizures or an early adjunctive agent for refractory 
absence seizures.
Status epilepticus
Intravenous LEV may be considered in the treatment of 
nonconvulsive or focal status epilepticus refractory to initial 
therapy. In this setting, the risk of general anesthesia may 
outweigh the risk of neuronal injury from ongoing seizure 
activity, such that additional nonsedating antiepileptic 
therapy may be used. The dose of intravenous LEV should 
probably be 1000–1500 mg administered over 5 minutes. 
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with standard intravenous therapy (usually lorazepam 
followed by fosphenytoin or phenytoin). General anesthesia 
should be considered next if initial therapy is not effective. 
LEV may be used only if it can be added without delay-
ing standard therapy or general anesthesia when standard 
therapy fails.
Dosing recommendations
The prescribing information recommends an adult starting 
dose of 1000 mg/day (500 mg twice daily), with subsequent 
escalation by 1000 mg every 2 weeks up to 1500 mg twice 
daily. These recommendations are based on the dose used in 
pivotal trials. Using evidence from post-marketing analyses, 
the author favors a smaller starting dose of 250 mg twice 
daily, with escalation to 500 mg twice daily after 1 week if 
the starting dose is well tolerated. In patients at higher risk for 
behavioral – psychiatric adverse effects, the starting dose can 
even be smaller, at 250 mg at bedtime. The same approach 
can be used with the elderly who have a higher chance of 
experiencing adverse effects on LEV. A starting dose of 500 
mg twice daily can still be considered in hospitalized patients 
who need faster efﬁ  cacy. Automatic escalation of the LEV 
dose to 3000 mg/day is usually not necessary. In patients with 
infrequent seizures, for whom the minimal effective dose 
can be hard to determine, the LEV dose can be escalated to 
1000 mg twice daily. The dose of LEV can be increased up 
to 3000 mg/day for persistent seizures. Even though there 
is no clear beneﬁ  t beyond 3000 mg/day, the LEV dose can 
be increased to 4000 mg/day for patients who have clearly 
responded to LEV, but have residual breakthrough seizures. 
However, the treating physician has to be aware of the risk 
of seizure exacerbation at higher LEV doses.
The same dosing guidelines can be applied to children. 
The ofﬁ  cial prescribing information recommends starting at 
20 mg/kg/day in 2 divided doses, with subsequent increments 
of 20 mg/kg every 2 weeks up to 60 mg/kg/day. However, 
starting at 10 mg/kg may reduce the frequency or intensity of 
behavioral adverse effects and provide a greater opportunity 
to manage these adverse effects rather than stop LEV. The 
target dose should be tailored to the patient, such that escala-
tion to 60 mg/kg/day may not be necessary.
Summary
In summary LEV should be considered as an initial or early 
add-on therapy for partial epilepsy, initial or early add-on 
therapy for myoclonic seizures in patients with juvenile 
myoclonic epilepsy, and as an early add-on therapy for 
patients with generalized tonic-clonic seizures in the setting 
of idiopathic generalized epilepsy. There is also evidence to 
support use of LEV as initial monotherapy in partial epilepsy, 
but other indications are not supported by pivotal trials.
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